Journal of Mathematical Biology

, Volume 67, Issue 5, pp 1111–1139 | Cite as

The role of backward mutations on the within-host dynamics of HIV-1

  • John M. Kitayimbwa
  • Joseph Y. T. Mugisha
  • Roberto A. Saenz


The quality of life for patients infected with human immunodeficiency virus (HIV-1) has been positively impacted by the use of antiretroviral therapy (ART). However, the benefits of ART are usually halted by the emergence of drug resistance. Drug-resistant strains arise from virus mutations, as HIV-1 reverse transcription is prone to errors, with mutations normally carrying fitness costs to the virus. When ART is interrupted, the wild-type drug-sensitive strain rapidly out-competes the resistant strain, as the former strain is fitter than the latter in the absence of ART. One mechanism for sustaining the sensitive strain during ART is given by the virus mutating from resistant to sensitive strains, which is referred to as backward mutation. This is important during periods of treatment interruptions as prior existence of the sensitive strain would lead to replacement of the resistant strain. In order to assess the role of backward mutations in the dynamics of HIV-1 within an infected host, we analyze a mathematical model of two interacting virus strains in either absence or presence of ART. We study the effect of backward mutations on the definition of the basic reproductive number, and the value and stability of equilibrium points. The analysis of the model shows that, thanks to both forward and backward mutations, sensitive and resistant strains co-exist. In addition, conditions for the dominance of a viral strain with or without ART are provided. For this model, backward mutations are shown to be necessary for the persistence of the sensitive strain during ART.


Within-host model HIV-1 Drug resistance Virus mutations 

Mathematics Subject Classification



  1. Boffito M, Winston A, Owen A (2005) Host determinants of antiretroviral activity. Curr Opin Infect Dis 18(6):543–549CrossRefGoogle Scholar
  2. Bonhoeffer S, Nowak MA (1997) Pre-existence and emergence of drug resistance in HIV-1 infection. Proc Roy Soc B 264(1382):631–637CrossRefGoogle Scholar
  3. Buckley RM, Gluckman SJ (2002) HIV infection in primary care. W. B. Saunders Company, An imprint of Elsevier Science, PhiladelphiaGoogle Scholar
  4. Burkle WS (2002) Antiretroviral therapy for HIV: drug resistance and sequencing. J Assoc Nurses AIDS Care 13(1):76–80CrossRefGoogle Scholar
  5. Carr J (1981) Applications of centre manifold theory. Springer, New YorkCrossRefMATHGoogle Scholar
  6. Castillo-Chávez C, Song BJ (2004) Dynamical models of tuberculosis and their applications. Math Biosci Eng 1:361–404MathSciNetCrossRefMATHGoogle Scholar
  7. Castillo-Chávez C, Feng C, Huang W (2002) In: Castillo-Cháve C et al (eds) On the computation of \(R_0\) and its role on global stability., Mathematical approaches for emerging and reemerging infectious diseases: an introduction. IMA, MinneapolisGoogle Scholar
  8. Deeks SG (2003) Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362(9400):2002–2011CrossRefGoogle Scholar
  9. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellman NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM (2001) Virological and immunological consequences of discontinuing combinational antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472–480Google Scholar
  10. Eron JJ, Benoit SL, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200500 CD4+ cells per cubic millimeter. N Engl J Med 333:1662–1669CrossRefGoogle Scholar
  11. Frost SDW, Nijhuis M, Schuurman R, Boucher CAB, Brown Leigh AJ (2000) Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74(14):6262–6268CrossRefGoogle Scholar
  12. Gonzalez RG, Cheng LL, Westmoreland SV, Sakaie KE, Becerra LR, Lee PL, Masliah E, Lackner AA (2000) Early brain injury in the SIV-macaque model of AIDS. AIDS 14:2841–2849CrossRefGoogle Scholar
  13. Hecht FM, Grant RM (2005) Resistance testing in drug-naïve HIV-infected patients: is it time? Clin Infect Dis 41:1324–1325CrossRefGoogle Scholar
  14. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, Stone VE, Smith DK, Schoenbaum EE (2002) A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16:2175–2182CrossRefGoogle Scholar
  15. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM (2011) Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203:1174–1181CrossRefGoogle Scholar
  16. Kane BM (2008) DRUGS, the straight facts: HIV/AIDS treatment drugs. Chelsea House Publishers, PhiladelphiaGoogle Scholar
  17. Kepler TB, Perelson AS (1998) Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci 95:11514–11519Google Scholar
  18. Kuritzkes DR (2004) Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs 18(5):259–273CrossRefGoogle Scholar
  19. Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731–1734CrossRefGoogle Scholar
  20. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69(8):5087–5094Google Scholar
  21. Markowitz M, Louie M, Hurley A, Sun E, Mascio MD, Perelson AS, Ho DD (2003) A novel antiviral intervention results in more accurate assessment of human immunodeciency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77:5037–5038CrossRefGoogle Scholar
  22. McLean AR, Nowak MA (1992) Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 6:71–79CrossRefGoogle Scholar
  23. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD (1998) Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279:1223–1227CrossRefGoogle Scholar
  24. Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, LondonGoogle Scholar
  25. Nowak MA, Bonhoeffer S, Shaw GM, May RM (1997) Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 184:203–217CrossRefGoogle Scholar
  26. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000) Adherence to protease inhibitor therapy an outcomes in patients with HIV infection. Ann Intern Med 133:21–30CrossRefGoogle Scholar
  27. Perelson AS (2002) Modeling viral and immune system dynamics. Nature 2:28–36Google Scholar
  28. Perelson AS, Kirschner DE, De Boer R (1993) Dynamics of HIV infection of CD4+ lymphocytes in vivo. Math Biosci 114:81–125CrossRefMATHGoogle Scholar
  29. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582–1586CrossRefGoogle Scholar
  30. Perelson AS, Essunger P, Ho DD (1997) Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 11: S17–S24Google Scholar
  31. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354:1782–1785Google Scholar
  32. Ribeiro RM, Bonhoeffer S (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci 97:7681–7686CrossRefMATHGoogle Scholar
  33. Rong L, Feng Z, Perelson AS (2007) Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull Math Biol 247:804–818MathSciNetGoogle Scholar
  34. UNAIDS (2009) Report on the global AIDS epidemic.
  35. Vaidya NK, Rong L, Marconi VC, Kuritzkes DR, Deeks SG, Perelson AS (2010) Treatment mediated alterations in HIV preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol 6(11):e1001012. doi:10.1371/journal.pcbi.1001012 MathSciNetCrossRefGoogle Scholar
  36. van den Driessche P, Watmough J (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci 180:29–48MathSciNetCrossRefMATHGoogle Scholar
  37. Wainberg MA, Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977–1983CrossRefGoogle Scholar
  38. Weber J, Rangel HR, Meyer PR, Chakraborty B, Tadele M, Martinez MA, Martinez-Picado J, Marotta ML, Mirza M, Ruiz L, Clotet B, Wrin T, Petropoulos CJ, Quinones-Mateu ME (2003) A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeciency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol 84:2217–2228CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • John M. Kitayimbwa
    • 1
  • Joseph Y. T. Mugisha
    • 1
  • Roberto A. Saenz
    • 2
    • 3
  1. 1.Department of MathematicsMakerere UniversityKampalaUganda
  2. 2.Institute of Integrative BiologyETH Zürich, ETH-Zentrum CHNZurichSwitzerland
  3. 3.CUICBAS, Facultad de CienciasUniversidad de ColimaColimaMexico

Personalised recommendations